LGL Group (NYSEAMERICAN:LGL) Stock Crosses Above 200-Day Moving Average – What’s Next?

Shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.51 and traded as high as $7.21. LGL Group shares last traded at $7.21, with a volume of 2,522 shares traded.

LGL Group Trading Up 4.5%

The stock has a market capitalization of $47.15 million, a PE ratio of 65.55 and a beta of 0.34. The company’s 50 day simple moving average is $7.13 and its 200 day simple moving average is $6.51.

LGL Group (NYSEAMERICAN:LGL) last released its earnings results on Monday, March 30th. The industrial products company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.09). The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $9.10 million. LGL Group had a return on equity of 1.62% and a net margin of 16.50%. As a group, analysts predict that LGL Group, Inc. will post 0.12 EPS for the current year.

Hedge Funds Weigh In On LGL Group

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC purchased a new stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned about 0.25% of LGL Group as of its most recent SEC filing. 30.28% of the stock is currently owned by institutional investors and hedge funds.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.